Comparative Pharmacology
Head-to-head clinical analysis: LIDOSITE TOPICAL SYSTEM KIT versus SCANDONEST L.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIDOSITE TOPICAL SYSTEM KIT versus SCANDONEST L.
LIDOSITE TOPICAL SYSTEM KIT vs SCANDONEST L
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is an amide-type local anesthetic that stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting the initiation and conduction of nerve impulses.
Scandonest L (mepivacaine hydrochloride) is an amide-type local anesthetic that stabilizes neuronal membranes by inhibiting sodium ion influx across the membrane, thereby blocking nerve impulse initiation and conduction.
Apply up to 3 patches topically once daily for up to 12 hours per day. Maximum 3 patches (210 mg lidocaine) per day.
Dental infiltration or nerve block: 1.3 mL of 3% solution (isocaine) per site; maximum 9 mg/kg (0.3 mL/kg) per session. Infiltration: 0.5-1.0 mL; nerve block: 1.0-1.3 mL.
None Documented
None Documented
1.5-2 hours (terminal); prolonged in hepatic dysfunction or heart failure
Terminal elimination half-life is 1.5–2.0 hours in healthy adults; prolonged to 3–5 hours in patients with hepatic impairment or severe renal disease.
Renal (80-90% as metabolites, <10% unchanged), biliary/fecal (minor, <5%)
Primarily hepatic metabolism (approx. 90%) via amidase hydrolysis and aromatic hydroxylation; renal excretion of unchanged drug accounts for <5% of the dose; less than 1% excreted in feces.
Category C
Category C
Local Anesthetic
Local Anesthetic